Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?

被引：0
|
作者：
Hideaki Yamakawa
Tamiko Takemura
Tae Iwasawa
Yumie Yamanaka
Satoshi Ikeda
Akimasa Sekine
Hideya Kitamura
Tomohisa Baba
Shinichiro Iso
Koji Okudela
Kazuyoshi Kuwano
Takashi Ogura
机构：
[1] Kanagawa Cardiovascular and Respiratory Center,Department of Respiratory Medicine
[2] Japanese Red Cross Medical Center,Department of Pathology
[3] Kanagawa Cardiovascular and Respiratory Center,Department of Radiology
[4] Yokohama Rousai Hospital for Labour Welfare Corporation,Department of Radiology
[5] Yokohama City University Graduate School of Medicine,Department of Pathobiology
[6] Tokyo Jikei University Hospital,Department of Respiratory Medicine
来源：
BMC Pulmonary Medicine | / 18卷
关键词：
Systemic sclerosis; Emphysematous change; Vasculopathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Defining genetic risk factors for scleroderma-associated interstitial lung disease IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease
    Stock, Carmel J. W.
    De Lauretis, Angelo
    Visca, Dina
    Daccord, Cecile
    Kokosi, Maria
    Kouranos, Vasilis
    Margaritopoulos, George
    George, Peter M.
    Molyneaux, Philip L.
    Nihtyanova, Svetlana
    Chua, Felix
    Maher, Toby M.
    Ong, Voon
    Abraham, David J.
    Denton, Christopher P.
    Wells, Athol U.
    Wain, Louise V.
    Renzoni, Elisabetta A.
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (04) : 1173 - 1179
  • [22] Defining genetic risk factors for scleroderma-associated interstitial lung diseaseIRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease
    Carmel J. W. Stock
    Angelo De Lauretis
    Dina Visca
    Cecile Daccord
    Maria Kokosi
    Vasilis Kouranos
    George Margaritopoulos
    Peter M. George
    Philip L. Molyneaux
    Svetlana Nihtyanova
    Felix Chua
    Toby M. Maher
    Voon Ong
    David J. Abraham
    Christopher P. Denton
    Athol U. Wells
    Louise V. Wain
    Elisabetta A. Renzoni
    [J]. Clinical Rheumatology, 2020, 39 : 1173 - 1179
  • [23] THE STABILIZATION OF LUNG FUNCTION IN PATIENTS WITH SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE DURING MYCOPHENOLATE MOFETIL THERAPY
    Koneva, O.
    Ananjeva, L.
    Korzeneva, L.
    Alekperov, R.
    Desinova, O.
    Starovoytova, M.
    Nevskaja, T.
    Ovsjannikova, O.
    [J]. RHEUMATOLOGY, 2012, 51 : 84 - 84
  • [24] Cyclophosphamide refractory scleroderma-associated interstitial lung disease: dramatic clinical and radiological response to rituximab
    Haroon, M.
    Ryan, J. G.
    Henry, M.
    Harney, S.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S173 - S173
  • [25] SERUM CYFRA 21-1 AS A PROGNOSTIC MARKER IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Stock, C. J. W.
    Hoyles, R.
    D'accord, C.
    Kokosi, M.
    Alfieri, V.
    Campochiaro, C.
    Donovan, J.
    Mori, L.
    Maher, T. M.
    Kouranos, V.
    Margaritopoulos, G.
    George, P. M.
    Molyneaux, P. L.
    Chua, F.
    Abraham, D. J.
    Ong, V.
    Denton, C. P.
    Wells, A. U.
    Renzoni, E. A.
    [J]. THORAX, 2018, 73 : A89 - A90
  • [26] A CASE OF SYSTEMIC SCLEROSIS SINE SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE WITHOUT A POSITIVE ANA?
    Djondo, Daniel
    [J]. CHEST, 2018, 154 (04) : 957A - 957A
  • [27] Evaluation of Efficacy, Immunogenicity, and Toxicity of a Novel Drug Candidate for Scleroderma-associated Interstitial Lung Disease
    Bogatkevich, Galina
    Atanelishvili, Ilia
    Perry, C. Beth
    Silver, Richard
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2324 - 2325
  • [28] Angiogenic and angiostatic factors in renal scleroderma-associated vasculopathy
    Gigante, Antonietta
    Navarini, Luca
    Margiotta, Domenico
    Amoroso, Antonio
    Barbano, Biagio
    Cianci, Rosario
    Afeltra, Antonella
    Rosato, Edoardo
    [J]. MICROVASCULAR RESEARCH, 2017, 114 : 41 - 45
  • [29] MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM THE AUSTRALIAN SCLERODERMA COHORT STUDY
    Owen, C.
    Ngian, G.
    Moore, O.
    Stevens, W.
    Proudman, S.
    Roddy, J.
    Zochling, J.
    Nash, P.
    Hill, C.
    Sturgess, A.
    Sahhar, J.
    [J]. INTERNAL MEDICINE JOURNAL, 2014, 44 : 36 - 36
  • [30] Asymptomatic pericardial disease in scleroderma-associated progressive interstitial lung disease and its relationship to pulmonary hypertension.
    Fischer, A
    Meehan, RT
    Ulrich, SK
    Curran-Everett, D
    Brown, KK
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S170 - S170
12345